InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Aardvark Therapeutics, Inc.

AARD Clue Score40
United States Fiscal year ends December CIK 0001774857
$4.45 -6.51% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.45 −69.58% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 13 Feb 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Operating income−22.8Net income−20.6EPS, diluted−5.15Fiscal year 2025Revenue0.0Operating income−62.7Net income−57.6EPS, diluted−2.93
FY2024FY2025
Revenue n/a 0.0
Growth
Operating income −22.8 −62.7
Net income −20.6 −57.6
Growth
EPS, diluted −5.15 −2.93

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−18.1Capital expenditure−0.1Free cash flow−18.2Fiscal year 2025Operating cash flow−54.2Capital expenditure−0.1Free cash flow−54.3
FY2024FY2025
Operating cash flow −18.1 −54.2
Capital expenditure −0.1 −0.1
Free cash flow −18.2 −54.3
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash61.6Shareholders’ equity−54.6Fiscal year 2025Cash47.1Shareholders’ equity106.6
FY2024FY2025
Cash 61.6 47.1
Shareholders’ equity −54.6 106.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −54.0%
−26.6% −49.1%
Balance and payout
7.0% 9.0%